EE338 Cost-Effectiveness of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis Versus Current Use of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine or No PrEP to Prevent HIV-1 in Individuals at High Risk in Spain
Abstract
Authors
V Neches K Campbell P Coll S Moreno Guillén JM Martínez-Sesmero F López Seguí P O'Brien A Davis SJ Anderson M Schroeder LA Vallejo-Aparicio